Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Thoracic Neoplasms 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Lung Neoplasms 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

durvalumab 3Carboplatin 2sotorasib 1sintilimab 1necitumumab 1ceralasertib 1camrelizumab 1apatinib 1alectinib 1Radiotherapy 1Radiosurgery 1Gemcitabine 1Etoposide 1Erlotinib Hydrochloride 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Respiratory Tract Diseases × necitumumab × Clear all
NCT02941601 2019-09-27

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Withdrawn
Thoracic

Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡